Anaphylaxis prevention, action plans and autoinjectors

Overview & Definition

Imagine a six-year-old with a peanut allergy sitting in a school lunch area. In the next ten minutes one of two things will happen: either nothing, because everyone knew the trigger, carried the plan and the device, and the food was kept away — or a collapse, and in that collapse the difference between life and death is whether a written plan and an adrenaline autoinjector exist on site and whether someone present can use them. This page is about building that package so reliably that the second scenario is survivable. [10]

Anaphylaxis prevention in children is the structured, longitudinal package that converts a potentially fatal allergic emergency into a treatable community event. It rests on five pillars: identification and avoidance of the trigger, a written personalised action plan, a prescribed adrenaline autoinjector, education of the child and every carer, and a medical alert plus a second device. The package is global, but its drugs, weight bands and named documents are regional — in Australia and Aotearoa New Zealand it is delivered through the ASCIA plans and devices, in Europe through the EAACI framework, and in North America through the AAAAI/ACAAI 2020 practice parameter. [5] [4]

The concept to hold is that prevention here is layered. Primary prevention is stopping food allergy from developing in the first place — the LEAP trial proved that early rather than delayed peanut introduction in high-risk infants cuts peanut allergy, and that upstream work reduces the downstream population this page's package exists to protect. [14] Secondary prevention is what happens after the diagnosis: avoidance, preparedness, the plan and the device. Tertiary prevention is preventing the next reaction from killing once anaphylaxis has already occurred — adrenaline without delay, the second dose, ambulance, observation. Every paragraph below sits inside one of these three layers. [9]